| Literature DB >> 35886453 |
Anna M Jambrina1,2, Neus Rams1, Pilar Rius3, Maria Perelló2,3, Montserrat Gironès3, Clara Pareja1, Francisco José Pérez-Cano2,4, Àngels Franch2,4, Manel Rabanal1,2,4.
Abstract
Traditionally, health sentinel networks have focused on the reporting of data by primary care physicians and hospitals, ignoring the role of the community pharmacist as an expert in drugs. The objective of this study was to describe a method for creating a network of sentinel pharmacies in a region of Southern Europe in order to have a pharmaceutical surveillance system that is representative of the territory to be monitored and that can respond to any events or incidents that can be followed up by the community pharmacy. The creation process was carried out in three phases: a first phase of selection through a cluster and population analysis and a final adjustment, a second phase of voluntariness and random selection, and a third phase of training and implementation of the network. A sentinel network of 75 community pharmacies has been established in Catalonia. The network monitors 2.47% of the total population with a homogeneous proportion of urban (42), rural (30), and mountain-area (3) pharmacies based on the particular characteristics of the territory. This model allows increased surveillance in the territory, objectively and representatively detects problems arising from the use of medicines, and establishes improvement strategies of public health.Entities:
Keywords: community health; community pharmacies; health services administration; pharmacies sentinel network; pharmacist intervention; pharmacy; public health
Mesh:
Year: 2022 PMID: 35886453 PMCID: PMC9324754 DOI: 10.3390/ijerph19148600
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Figure 1Health map of Catalonia distributed into health regions (A), health sectors (B), and basic health areas (C). The names of the health regions are included in panel (A) and the codes of both the health regions and the health sectors are also included in panels (A) and (B), respectively. Health sector codes are based on the health sector root code.
Cluster analysis to obtain the proportion of pharmacies in each HR.
| HR | HS (n) | BHA (n) | BHA Type 1 | Ratio 2 |
|---|---|---|---|---|
| Alt Pirineu i Aran | 2 | 8 | 0:4:4 | 0:1:1 |
| Lleida | 1 | 23 | 7:16:0 | 1:2:0 |
| Camp de Tarragona | 3 | 33 | 16:17:0 | 1:1:0 |
| Terres de l’Ebre | 1 | 11 | 2:9:0 | 1:4:0 |
| Girona | 2 | 41 | 7:28:6 | 1:8:1 |
| Catalunya Central | 3 | 38 | 11:18:9 | 1:2:1 |
| Barcelona | 17 | 220 | 184:36:0 | 5:1:0 |
1 Number of uBHA, rBHA, and mBHA in each HR. 2 Proportion of urban, rural, and mountain-area pharmacies in each HR.
Population analysis to obtain the minimum number of pharmacies in each HR.
| HR | Population (n) | 2% Population | Pharmacies (n) |
|---|---|---|---|
| Alt Pirineu i Aran | 71,888 | 1438 | 1 |
| Lleida | 361,702 | 7234 | 3 |
| Camp de Tarragona | 617,504 | 12,350 | 5 |
| Terres de l’Ebre | 178,398 | 3568 | 2 |
| Girona | 865,282 | 17,306 | 7 |
| Catalunya Central | 519,836 | 10,397 | 5 |
| Barcelona | 4,985,459 | 99,709 | 40 |
|
|
|
|
|
Population analysis to obtain the minimum number of pharmacies per HR.
| HR | Ratio CA 1 | Pharmacies (n) PA 2 | Pharmacies (n) 3 | Special Characteristics | Total Pharmacies (n) |
|---|---|---|---|---|---|
| Alt Pirineu i Aran | 0:1:1 | 1 | 2 (0U, 1R, 1M) | None | 2 (0U, 1R, 1M) |
| Lleida | 1:2:0 | 3 | 3 (1U, 2R, 0M) | Since 1 urban pharmacy did not ensure 2% of the urban population was monitored, the ratio was expanded to 2 urban and 4 rural pharmacies. | 6 (2U, 4R, 0M) |
| Camp de Tarragona | 1:1:0 | 5 | 6 (3U, 3R, 0M) | Since 3 urban pharmacies did not ensure 2% of the urban population was monitored, it was expanded to 4 urban and 4 rural pharmacies. | 8 (4U, 4R, 0M) |
| Terres de l’Ebre | 1:4:0 | 2 | 5 (1U, 4R, 0M) | A much larger number of rural than urban inhabitants were monitored, which could lead to a representativeness bias. To equate the two population groups, the number of rural pharmacies was reduced to 2. | 3 (1U, 2R, 0M) |
| Girona | 1:8:1 | 7 | 10 (1U, 8R, 1M) | Given that 1 urban pharmacy did not ensure 2% of the urban was population monitored and that the ratio allowed for a second urban pharmacy, 2 urban pharmacies were selected. | 11 (2U, 8R, 1M) |
| Catalunya Central | 1:2:1 | 5 | 5 (1U, 2R, 1M, and 1 uncategorized) | Given that at least 5 pharmacies were needed and that the ratio allowed for a second urban pharmacy, 2 urban pharmacies were selected. | 5 (2U, 2R, 1M) |
| Barcelona | 5:1:0 | 40 | 40 (32U, 8R, 0M) | None | 40 (32U, 8R, 0M) |
1 CA: Cluster analysis. 2 PA: Population analysis. 3 Number of pharmacies according to the two analyses (CA and PA) and the number of urban pharmacies (U), rural pharmacies (R), and mountain-area pharmacies (M).
Figure 2Map of the final territorial distribution of the 75 pharmacy offices of the sentinel pharmacy network of Catalonia.
Activities carried out for the network of sentinel pharmacies in Catalonia during the 2017–2021 period.
| Area of Intervention | Name of Activity | Duration | Collected |
|---|---|---|---|
| Pharmacovigilance | Monitoring of pharmaceutical quality alerts | 5 years | 4918 |
| Pharmacovigilance | Notification of medication errors | 5 years | 1676 |
| Pharmacovigilance | Notification of suspected adverse drug reactions | 5 years | 582 |
| Pharmacovigilance | Additional follow-up of treatment with SGLT2 inhibitors | 1 year | 505 |
| Pharmacovigilance | Monitoring of the dispensing of valproic acid in adult women of gestational age | 2.5 years | 91 |
| Pharmacovigilance | Monitoring of the dispensing of isotretinoin in adult women of gestational age | 1 year | 98 |
| Observatory of drug abuse | Monitoring of abuse or recreational use of medications [ | 5 years | 1229 |
| Observatory of drug abuse | Use of tramadol for non-oncologic pain | 2 years | 266 |
| Public health | Characterization of the use of emergency contraception [ | 2 years | 941 |
| Public health | Influenza syndromic surveillance [ | 5 years | 1986 |
Validated questionnaire templates for sentinel pharmacy data collection.
| Area of Intervention | Name of Activity | Question Number | Question Text |
|---|---|---|---|
| Pharmacovigilance | Monitoring of pharmaceutical quality alerts | 1 | Pharmacy ID |
| 2 | Pharmaceutical alert ID | ||
| 3 | Reception date of the alert | ||
| 4 | Reception channel of the alert | ||
| 5 | Has pharmacy staff been informed? | ||
| 6 | Are batches of the drug affected in your pharmacy? | ||
| 7 | Date of withdrawal of the batch medicine | ||
| Observatory of drug abuse | Monitoring of abuse or recreational use of medications | 1 | Pharmacy ID |
| 2 | Pharmacist | ||
| 3 | Patient age | ||
| 4 | Patient sex | ||
| 5 | Patient origin (native or not) | ||
| 6 | Substance involved | ||
| 7 | Drug request (prescription or not) | ||
| 8 | Request with or not intimidation | ||
| 9 | Frequent request? | ||
| 10 | Pharmacist management? | ||
| 11 | Why do you supply the medicine? | ||
| 12 | Observations | ||
| Public Health | Characterization of the use of emergency contraception (EC) | 1 | Pharmacy ID |
| 2 | Data of EC dispensation | ||
| 3 | National code and name of medicinal product | ||
| 4 | User sex (male, female) | ||
| 5 | Age of the user | ||
| 6 | Whom the medication is for? | ||
| 7 | Population of residence | ||
| 8 | Time from unprotected sex (hours) | ||
| 9 | Time since the last menstrual period (weeks) | ||
| 10 | Contraceptive method normally used | ||
| 11 | First EC dispensation or not | ||
| 12 | Suspected adverse reactions reported? | ||
| 13 | Description of pharmaceutical action performed | ||
| 14 | Availability of an EC kit consisting of a condom and additional informative material (yes or not) | ||
| 15 | Observations |